Abdominal bloating is a common symptom, newly defined in the Rome IV criteria as recurrent sensations of bloating, pressure, and gas retention lasting at least six months. It often coexists with mild pain and bowel irregularities, particularly in patients with constipation predominant IBS and functional constipation. Epidemiologically, 16–31% of the general population experience bloating, with women more affected than men. Symptoms significantly impair quality of life for many patients. The pathophysiology is multifactorial: increased gastrointestinal contents (gas, stool, liquid, fat), motility disorders, abnormal viscerosomatic reflexes causing muscle relaxation, and visceral hypersensitivity possibly influenced by hormones and psychological factors. Gas accumulation is linked to swallowing air, fermentation, and bacterial overgrowth like small intestinal bacterial overgrowth (SIBO). Stool retention, liquid presence after meals, and fat accumulation also contribute. Diagnosis follows Rome IV criteria, requiring symptom duration and frequency. Warning signs warrant exclusion of organic disease through tests. Treatment includes lifestyle modifications such as a low-FODMAP diet, exercise to strengthen abdominal muscles, and pharmacotherapy including probiotics, herbal medicines, simethicone, and sometimes antibiotics or antidepressants. Psychological therapies like cognitive-behavioral therapy are also tried. While not life-threatening, functional abdominal bloating reduces quality of life. Tailored treatment and a positive therapeutic relationship improve outcomes.